Bioventus (BVS) vs Tactile Systems Technology (TCMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Bioventus (BVS) has outperformed Tactile Systems Technology (TCMD) over the past year, gaining 36.5% versus a loss of 0.4%. Over five years, TCMD leads with a +23.9% price change compared with -21.0% for BVS. Bioventus is the larger company by market cap ($676.5 million vs $573.5 million), about 1.2 times the size, while Tactile Systems Technology is growing revenue faster (+12.5% vs -0.9%).
On valuation, Bioventus trades at a lower forward P/E (11.1x vs 17.4x for Tactile Systems Technology). Tactile Systems Technology converts more of its revenue into profit, with a net margin of 5.8% versus 4.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BVS | TCMD |
|---|---|---|
| Share price | $9.88 | $25.60 |
| Market cap | $676.53M | $573.48M |
| 1-day change | -0.70% | -1.50% |
| YTD return | +32.80% | -11.72% |
| 1-year return | +36.46% | -0.39% |
| 5-year return | -21.02% | +23.85% |
| P/E ratio (TTM) | 12.20 | 24.85 |
| Forward P/E | 11.13 | 17.41 |
| EPS (TTM) | $0.81 | $1.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $568.09M | $329.52M |
| Revenue growth (YoY) | -0.91% | +12.47% |
| Net income (latest FY) | $22.73M | $19.09M |
| Gross margin | 68.33% | 75.91% |
| Operating margin | 9.50% | 8.89% |
| Net margin | 4.00% | 5.79% |
| 52-week high | $15.89 | $37.77 |
| 52-week low | $7.02 | $20.53 |
| Distance from 52-week high | -37.83% | -32.22% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +68.02% | +41.91% |
| Average volume | 536.81K | 248.63K |
| Shares outstanding | 68.47M | 22.40M |
| Employees | 960 | 1,086 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BVS has outperformed TCMD by 36.9 percentage points over the past year.
- Tactile Systems Technology trades at a higher earnings multiple (24.9x vs 12.2x trailing P/E).
- Tactile Systems Technology grew revenue faster in its latest fiscal year (+12.47% vs -0.91%).
About Bioventus
BVS stock →Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle.
Health Care · Medical/Dental Instruments · 960 employees
About Tactile Systems Technology
TCMD stock →Tactile Systems Technology, Inc., a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema, phlebolymphedema, lipedema, venous insufficiencies, and other types of edema and leg ulcers; Entre Plus System, a pneumatic compression device for the at-home treatment of lymphedema, chronic edema, venous insufficiency, and chronic wounds.
Health Care · Medical/Dental Instruments · 1,086 employees
BVS vs TCMD FAQ
Which is bigger, Bioventus or Tactile Systems Technology?
Bioventus (BVS) is larger, with a market capitalization of $676.53M compared with $573.48M for Tactile Systems Technology (TCMD).
Which stock has performed better over the past year, BVS or TCMD?
BVS returned +36.46% over the past 12 months, compared with -0.39% for TCMD (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, BVS or TCMD?
BVS has the lower trailing P/E at 12.2, versus 24.9 for TCMD. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Bioventus and Tactile Systems Technology in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.